home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Courses and Workshops  
 

Granulation, Tabletting and Capsule Technology

 
  December 02, 2016  
     
 
CfPA-The Center for Professional Advancement, Salt Lake City, UT
April 25-28, 2017


Who Should Attend?
This broadly based course is intended for all scientists and technologists concerned with the development and processing of tablets, capsules and similar products, and with related drug regulatory affairs.

The material will be presented in such a way as to be of value to a varying level of expertise. This course will especially benefit those in:
  • Quality Assurance
  • Marketing
  • Validation 
  • Purchasing
  • R&D 
  • Regulatory Affairs
  • Manufacturing/Production 
  • Engineering Support

Note: Persons seeking an in-depth treatment of only one or two of the major topics of this broadly based program may wish to consider alternative, more specialized courses offered by CfPA in this area of technology.

Course Description
The main aim of this course is to review the science relating to tabletted and encapsulated pharmaceutical products. The course begins with a consideration of raw material testing and the basic aspects of powder and granulation technology, progresses through formulation of solid dosage forms to manufacturing processes and equipment including scaleup and technology transfer. The program concludes with key aspects of the evaluation of finished products and the regulatory constraints that must be considered at each stage.

Formal sessions of the course are supplemented with informal discussion periods between lecturers and course participants and problem-solving sessions are held on both an open and private basis.
 
 
Organized by: CfPA-The Center for Professional Advancement
Invited Speakers:
Course Director
Dr. Cecil W. Propst; Managing Director, Propst Consulting Services

Dr. Cecil W. Propst is Managing Director at Propst Consulting Services, a formulation, and engineering support LLC located in Norton Shores MI. He was Director of R&D (Grand Haven site) at SPI Pharma until 2015. He served as Director of Quality Assurance and Technical Services at Fleming and Company, and before that, President of Manufacturing Chemists. His duties included system design, product and process development and regulatory affairs. Previously, he served as cGMP Facilities Director for the University of Maryland at Baltimore, in connection with the University’s SUPAC contract with the FDA. Dr. Propst also served as Director of Technical Development for Stellar Manufacturing; Director of Quality Compliance for SmithKline Beecham; Director, Quality Assurance for Norcliff Thayer (a Revlon Company); and Group Leader/Product Development and Manager/Quality Control for Lewis Howe Company. He serves as a consultant in the area of product development and process investigations for the chemical, diagnostic, food, engineering and beverage industries.

Additional Faculty
Ms. Joy Joseph, Consultant to the Pharmaceutical Industry
Mr. Charles Cunningham, Technical Director, Colorcon Ltd.
Mr. Dilip Parikh, President and CEO DPharma Group
Dr. Martin Thomas, Director, Science and Technology, Quantachrome
 
Deadline for Abstracts: N/A
 
Registration: Please click here for registration information.
E-mail: Jmorbit@cfpa.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.